open access

Vol 18, No 1 (2015)
Original articles
Published online: 2015-01-29
Submitted: 2014-05-20
Accepted: 2014-11-18
Get Citation

A simple and accurate dosimetry protocol to estimate activity for hyperthyroidism treatment

Andrea Skanjeti, Anna Miranti, Gabriela Mariam Delgado Yabar, Davide Bianciotto, Edoardo Trevisiol, Michele Stasi, Valerio Podio
DOI: 10.5603/NMR.2015.0004
·
Pubmed: 25633511
·
Nucl. Med. Rev 2015;18(1):13-18.

open access

Vol 18, No 1 (2015)
Original articles
Published online: 2015-01-29
Submitted: 2014-05-20
Accepted: 2014-11-18

Abstract

BACKGROUND: Aim of the study was to evaluate accuracy of different dosimetry protocols in estimating the required 131I activity to treat hyperthyroid patients.

MATERIALS AND METHODS: Forty consecutive patients were analysed: twenty-eight Graves’ disease; twelve autonomous thyroid nodule (ATN). Maximum-uptake, effective half-time and residence-time were estimated from Radioiodine Uptake Test. Residence-time was estimated using a bi-compartmental model. For 131I activity calculation, algorithms laid down in European Association of Nuclear Medicine (EANM) guidelines, ICRP 53 approach and a mono-exponential formula (ME), were compared with OLINDA/EXM results.

RESULTS: Based on EANM guidelines, activities to be administered were 3% higher in Graves’ disease (p = 0.001) and 3% higher in ATN (p = 0.046). Calculated activities using ICRP 53 approach were significantly lower compared to OLINDA/EXM: 33% in Graves’ disease; 17% in ATN. Activities recommended by ME, were significantly higher: in Graves’ disease 20%; 42% in ATN.

CONCLUSIONS: Only EANM algorithm predict quite well, compared to OLINDA/EXM, the required activity to treat hyperthyroid patients.

Abstract

BACKGROUND: Aim of the study was to evaluate accuracy of different dosimetry protocols in estimating the required 131I activity to treat hyperthyroid patients.

MATERIALS AND METHODS: Forty consecutive patients were analysed: twenty-eight Graves’ disease; twelve autonomous thyroid nodule (ATN). Maximum-uptake, effective half-time and residence-time were estimated from Radioiodine Uptake Test. Residence-time was estimated using a bi-compartmental model. For 131I activity calculation, algorithms laid down in European Association of Nuclear Medicine (EANM) guidelines, ICRP 53 approach and a mono-exponential formula (ME), were compared with OLINDA/EXM results.

RESULTS: Based on EANM guidelines, activities to be administered were 3% higher in Graves’ disease (p = 0.001) and 3% higher in ATN (p = 0.046). Calculated activities using ICRP 53 approach were significantly lower compared to OLINDA/EXM: 33% in Graves’ disease; 17% in ATN. Activities recommended by ME, were significantly higher: in Graves’ disease 20%; 42% in ATN.

CONCLUSIONS: Only EANM algorithm predict quite well, compared to OLINDA/EXM, the required activity to treat hyperthyroid patients.

Get Citation

Keywords

Graves’ disease, autonomous thyroid nodule, radioiodine, MIRD, guidelines

About this article
Title

A simple and accurate dosimetry protocol to estimate activity for hyperthyroidism treatment

Journal

Nuclear Medicine Review

Issue

Vol 18, No 1 (2015)

Pages

13-18

Published online

2015-01-29

DOI

10.5603/NMR.2015.0004

Pubmed

25633511

Bibliographic record

Nucl. Med. Rev 2015;18(1):13-18.

Keywords

Graves’ disease
autonomous thyroid nodule
radioiodine
MIRD
guidelines

Authors

Andrea Skanjeti
Anna Miranti
Gabriela Mariam Delgado Yabar
Davide Bianciotto
Edoardo Trevisiol
Michele Stasi
Valerio Podio

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl